ZIOPHARM Oncology, Inc. is a company in the U.S. stock market and it is a holding in 40 U.S.-traded ETFs. ZIOP has around 13.5M shares in the U.S. ETF market. The largest ETF holder of ZIOP is the SPDR S&P Biotech ETF (XBI), with approximately 3.72M shares. Investors may also find of interest that the ETF with the largest allocation to ZIOP stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 3.24%. On average, U.S. ETFs allocate 0.19% of ZIOP to their portfolios.
Additionally, ZIOP is a favorite stock for Vanilla and Growth ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with ZIOP as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 34.78%.